Skip to main content
Article thumbnail
Location of Repository

Properdin in immunity: In vitro and in vivo investigations.

By Aline Dupont

Abstract

The complement system is one of the defence systems used by the host to protect\ud itself against pathogens. It is divided into three complement pathways: the antibodydependent classical pathway, the lectin pathway and the alternative pathway. This latter antibody-independent pathway is auto-activated and leads to the generation and the deposition of C3b molecules on the pathogen’s surface. Properdin, the only\ud positive regulator of this pathway, plays a major role by stabilising the alternative C3\ud convertase that leads to the creation of the amplification loop. Only little was known\ud about the biology of properdin at the beginning of this project, despite the fact that properdin was discovered more than 50 years ago and despite the important role\ud played by this molecule in immunity, as illustrated by the higher susceptibility to\ud severe meningococcal disease encountered by properdin-deficient people. My thesis\ud dealt with three experimental outlines to determine the role of properdin in immunity\ud Properdin was examined from its global expression by various organs to its specific\ud expression by different cell types. I have first shown using molecular biology and\ud bioinformatics tools that properdin was expressed at a relatively high level in different lymphoid organs. I have then examined in more detail the expression of properdin by one of these organs, namely the spleen, using immunofluorescence. Properdin was thus shown to be present only in the white pulp compartment of this organ, where it was organised in clusters of properdin-positive cells possessing long cytoplasmic\ud extensions.\ud Next, I studied the expression of properdin by auxiliary cells. I have first given\ud evidence that properdin was deposited on the surface of platelets and that this level of\ud deposition was related to the activation state of the platelets. I have then shown for the first time that properdin was expressed by two mast cell lines. Microscopic analyses then demonstrated that properdin was present on the mast cell membrane and was present mainly as clusters on membrane extensions similar to vesicles in the process of being released. Further analyses on vesicles released by mast cells confirmed that properdin was enriched in a fraction of vesicles similar in size and in shape to microvesicles.\ud Finally, the role played by properdin during bacterial infection was investigated using\ud a pneumococcal pneumonia model. This study showed that properdin-deficient mice\ud presented a worse level of infection than their wild-type littermates 2 days postinfection. This was associated with an unexpected higher survival rate for properdindeficient animals one week following the challenge. Therefore, in this model, while properdin was seen to be beneficial during the first 48 hours post-infection, by controlling the infection, the absence of properdin led to increased survival following infection. This study thus showed for the first time that properdin could play a bivalent role during infection, the higher inflammatory response engendered by properdin turning from being beneficial to being detrimental to the host over time

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/4244

Suggested articles

Citations

  1. (1969). A Low-Viscosity Epoxy Resin Embedding Medium for Electron Microscopy.
  2. (1995). A Pneumolysin-Negative Mutant of Streptococcus Pneumoniae Causes Chronic Bacteremia rather than Acute Sepsis in Mice.
  3. (2000). A Role for CD21/CD35 and CD19 in Responses to Acute Septic Peritonitis: A Potential Mechanism for Mast Cell Activation.
  4. (1988). A Second Variant of Properdin Deficiency: The Detection of Properdin at Low Concentrations in Affected Males.
  5. (2000). A Simple Method for Isolating Human and Rabbit Polymorphonuclear Neutrophils (PMNs).
  6. (2003). Absolute Quantitation of Normal and ROS-Induced Patterns of Gene Expression: An
  7. (1999). Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived from Exocytosis of Multivesicular Bodies and Alpha-Granules.
  8. (2005). Additive Inhibition of Complement Deposition by Pneumolysin and PspA Facilitates Streptococcus Pneumoniae Septicemia.
  9. (1981). Amino Acid Sequence Studies of Human Properdin – N-Terminal Sequence Analysis and Alignment of the Fragments Produced by Limited Proteolysis with Trypsin and the Peptides Produced by Cyanogen Bromide Treatment.
  10. (1958). An Alternative Mechanism for the Properdin System.
  11. (1989). Analysis of the Natural Polymeric Forms of Human Properdin and their Functions in Complement Activation.
  12. (1989). Another Swedish Family with Complete Properdin Deficiency: Association with Fulminant Meningococcal Disease in One Male Family Member.
  13. (2006). Association between Combined Properdin and MannoseBinding Lectin Deficiency and Infection with Neisseria Meningitidis.
  14. BioRad tech note,
  15. (1988). Biosynthesis of Complement Factor P (Properdin) by the Human Pre-Monocyte Cell Line (U-937).
  16. (1980). Biosynthesis of the Complement Components and the Regulatory Proteins of the Alternative Complement Pathway by Human Peripheral Blood Monocytes.
  17. (1948). Blutgerinnungsstudien Mit Der Thromboelastographie, Einem Neuen Untersuchungsverfahren.
  18. (2002). C-Mannosylation and O-Fucosylation of Thrombospondin Type 1 Repeats.
  19. (1996). Carrier Detection by Microsatellite Haplotyping in 10 Properdin Type 1-Deficient Families.
  20. (1993). Carrier Detection in Families with Properdin Deficiency by Microsatellite Haplotyping.
  21. (2003). Characterisation and Properties of Ectosomes Released by Human Polymorphonuclear Neutrophils.
  22. (1995). Characterization of Mutant Forms of Recombinant Human Properdin Lacking Single Thrombospondin Type I Repeats. Identification of Modules Important for Function.
  23. (1979). Characterization of the Continuous, Differentiating Myeloid Cell Line (HL-60) from a Patient with Acute Promyelocytic Leukemia.
  24. (1995). Cloning and Characterization of the cDNA Encoding Guinea-Pig Properdin: A Comparison of Properdin from Three Species.
  25. (2001). Complement Activation in Factor D-Deficient Mice.
  26. (1989). Complement Activation in Human Lymphoid Germinal Centres.
  27. (2007). Complement and Coagulation: Strangers Or Partners in Crime? Trends Immunol.
  28. (2006). Complement and Properdin Deficiencies in Meningococcal Disease.
  29. (1989). Complement Deficiencies in Patients Over Ten Years Old with Meningococcal Disease due to Uncommon Serogroups.
  30. (1989). Complement Deficiencies in Selected Groups of Patients with Meningococcal Disease.
  31. (2006). Complement Deficiency and Disease: An Update.
  32. (2004). Complement: A Unique Innate Immune Sensor for Danger Signals.
  33. (1987). Congenital Properdin Deficiency and Meningococcal Infection.
  34. (1996). Critical Protective Role of Mast Cells in a Model of Acute Septic Peritonitis.
  35. (1994). Degradation of C3 by Streptococcus Pneumoniae.
  36. (1997). Detection of Intracellular Interleukin-8 in Human Mast Cells: Flow Cytometry as a Guide for Immunoelectron Microscopy.
  37. (1993). Detection of Mosaic Protein mRNA in Human Astrocytes.
  38. (1997). Development of a Model of LowInoculum Streptococcus Pneumoniae Intrapulmonary Infection in Infant Rats.
  39. (2003). DigiNorthern, Digital Expression Analysis of Query Genes Based on ESTs.
  40. Direct Binding of C1q to Apoptotic Cells and Cell Blebs Induces Complement Activation.
  41. (1988). Dysfunctional Properdin in a Dutch Family with Meningococcal Disease.
  42. (1975). Effect of Pneumococci on Blood Clotting, Platelets, and Polymorphonuclear Leukocytes.
  43. (2001). Effects of antidepressant drugs on the behavoral and physiological responses to lipopolysaccharide (LPS) in rodents.
  44. (2003). Established from a Patient with Mast Cell sarcoma/leukemia; Activation Following Aggregation of FcεRI Or FcγRI.
  45. (1988). Establishment of an Immature Mast Cell Line from a Patient with Mast Cell Leukemia.
  46. (2005). Exosomal-Like Vesicles are Present in Human Blood Plasma.
  47. (2006). Exosomes: From Biogenesis and Secretion to Biological Function.
  48. (2001). Expression and Characterisation of the Thrombospondin Type I Repeats of Human Properdin.
  49. (1994). Expression of Properdin in Human Monocytes.
  50. (1987). Familial Properdin Deficiency and Fatal Meningococcemia. Correction of the Bactericidal Defect by Vaccination.
  51. (1989). Familial Properdin Deficiency Associated with Chronic Discoid Lupus Erythematosus.
  52. (1981). Fixation for Electron Microscopy.
  53. (2004). Flow-Cytometric Analysis of PlateletMembrane Glycoprotein Expression and Platelet Activation. Methods Mol.
  54. (1985). Formation of Soluble Immune Complexes by Complement
  55. (1983). Fulminant Meningococcal Infections in a Family with Inherited Deficiency of Properdin.
  56. (2004). Global Effect of PEG-IFN-α and Ribavirin on Gene Expression in PBMC in Vitro.
  57. (1991). Granulocyte Functions and Neisseria Meningitidis: Influence of ProperdinDeficient Serum.
  58. (1993). Hereditary Properdin Deficiency in Three Families of Tunisian Jews.
  59. (2000). Host Cellular Immune Response to Pneumococcal Lung Infection in Mice.
  60. (1997). Host Tissue Damage by Phagocytes.
  61. (1985). Human Follicular Dendritic Cells Express CR1, CR2, and CR3 Complement Receptor Antigens.
  62. (1994). Human Liver-Derived Hep G2 Cells Produce Functional Properdin.
  63. (2006). Human Monocyte-Derived Dendritic Cells are a Source of several Complement Proteins.
  64. (1997). Human Properdin Deficiency has a Heterogeneous Genetic Background.
  65. Identification of Mutations in the Coding Sequence of the Proto-Oncogene cKit in a Human Mast Cell Leukemia Cell Line Causing Ligand-Independent Activation of c-Kit Product.
  66. (2003). IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells.
  67. (1992). Induction of Procoagulant Activity on Human Endothelial Cells by Streptococcus Pneumoniae.
  68. (1991). Infectious Diseases Associated with Complement Deficiencies.
  69. (1995). Inherited Complement Deficiency in Children Surviving Fulminant Meningococcal Septic Shock.
  70. (1990). Inherited Complement Deficiency States: Implications for Immunity and Immunological Disease.
  71. (1987). Inherited Deficiency of Properdin and C2 in a Patient with Recurrent Bacteremia.
  72. (2004). Innate Immunity of the Sinonasal Cavity: Expression of Messenger RNA for Complement Cascade Components and Toll-Like Receptors.
  73. (2007). Interferon-Gamma Regulates Chemokine Expression and Release in the Human Mast Cell Line HMC-1: Role of Nitric Oxide.
  74. (1996). Interleukin-12 and Tumor Necrosis Factor Alpha Mediate Innate Production of
  75. (2005). Intraspecies and Temperature-Dependent Variations in Susceptibility of Yersinia Pestis to the Bactericidal Action of Serum and to Polymyxin B.
  76. (2006). Intrinsic Biological Activity of the Thrombospondin Structural Homology Repeat in Connective Tissue Growth Factor.
  77. (2000). Invasive Pneumococcal Disease in the Immunocompromised Host.
  78. (2002). Large-Scale Analysis of the Human and Mouse Transcriptomes.
  79. (2005). Lipopolysaccharide Activates Human Mast Cells to Induce Intestinal Epithelial Barrier Dysfunction. The Internet
  80. (2005). Macrophage Receptors and Immune Recognition.
  81. (2003). Malignant Hematopoietic Cell Lines: In Vitro Models for the
  82. (2006). Mannan-Binding Lectin (MBL)-Mediated Opsonization is Enhanced by the Alternative Pathway Amplification Loop.
  83. (2004). MAPK-Dependent Regulation of IL-1-and Beta-Adrenoreceptor-Induced Inflammatory Cytokine Production from Mast Cells: Implications for the Stress Response.
  84. (2004). Marginal Zone B Cells Transport and Deposit IgM-Containing Immune Complexes onto Follicular Dendritic Cells.
  85. (1996). Mast Cell Modulation of Neutrophil Influx and Bacterial Clearance at Sites of Infection through TNF-Alpha.
  86. (1998). Mast Cell Tryptase and its Role in Tissue Remodelling.
  87. (2001). Mast Cell-Dependent B and T Lymphocyte Activation is Mediated by the Secretion of Immunologically Active Exosomes.
  88. (2005). Mast Cell-Derived Exosomes Activate Endothelial Cells to Secrete Plasminogen Activator Inhibitor Type 1.
  89. (2007). Mast Cells – Key Effector Cells in Immune Responses. Trends Immunol.
  90. (2002). Mast Cells in Autoimmune Disease.
  91. (2008). Mast Cells: Versatile Regulators of Inflammation, Tissue Remodeling, Host Defense and Homeostasis.
  92. (2006). Membrane-Derived Microvesicles: Important and Underappreciated Mediators of Cell-to-Cell Communication.
  93. (2006). Microparticles as Mediators of Cellular Cross-Talk in Inflammatory Disease.
  94. (2005). Microparticles Released by Human Neutrophils Adhere to Erythrocytes in the Presence of Complement.
  95. (1984). Molecular Architecture of Human Properdin, a Positive Regulator of the Alternative Pathway of Complement.
  96. (2000). Molecular Characterisation of 10 Dutch Properdin Type I Deficient Families: Mutation Analysis and X-Inactivation Studies.
  97. (1996). Molecular Characterization of Properdin Deficiency Type III: Dysfunction Produced by a Single Point Mutation in Exon 9 of the Structural Gene Causing a Tyrosine to Aspartic Acid Interchange.
  98. (1991). Molecular Cloning of the cDNA Coding for Properdin, a Positive Regulator of the Alternative Pathway of Human Complement.
  99. (1991). Neutron and XRay Scattering Studies on the Human Complement Protein Properdin Provide an Analysis of the Thrombospondin Repeat.
  100. (1991). Normal Human Serum Depleted of C1q, Factor D and Properdin: Its use in Studies of Complement Activation.
  101. (2006). Normal Structure, Function,
  102. (2000). Opsonic and Nonopsonic Interactions of C3 with Streptococcus Pneumoniae.
  103. (1995). Partial Properdin Deficiency Revealed by a Septicemia Caused by Neisseria Meningitidis.
  104. (2003). Paul Ehrlich's Doctoral Thesis:
  105. (2004). Peroxynitrite Decreases Rabbit Tissue Factor Activity in Vitro.
  106. (1994). Phenotypic Characterization of the Human Mast-Cell Line HMC-1.
  107. (2005). Platelet Activation Leads to Activation and Propagation of the Complement System.
  108. (2001). Pneumococcal Virulence Factors: Structure and Function.
  109. (1980). Presidential Address to American Association of Immunologists in
  110. (1998). Primary Immunodeficiency Diseases in Latin America: First Report from Eight Countries Participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases.
  111. (1993). Profound Platelet Degranulation is an Important Side Effect of some Types of Contrast Media used in Interventional Cardiology.
  112. (2008). Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation.
  113. (2007). Properdin can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly.
  114. (1999). Properdin Deficiency and Meningococcal Disease – Identifying those most at Risk.
  115. (1982). Properdin Deficiency in a Family with Fulminant Meningococcal Infections.
  116. (1999). Properdin Deficiency in a Large Swiss Family: Identification of a
  117. (2008). Properdin Deficiency in Murine Models of Nonseptic Shock.
  118. (1999). Properdin Deficiency: Molecular Basis and Disease Association.
  119. (1998). Properdin Deficiency: Rare Presentation with Meningococcal Bone and Joint Infections.
  120. (2008). Properdin Plays a Protective Role in Polymicrobial Septic Peritonitis.
  121. (1993). Properdin, a Positive Regulator of Complement Activation, is Expressed in Human T Cell Lines and Peripheral Blood T Cells.
  122. (1997). Properdin, a Positive Regulator of Complement Activation, is Released from Secondary Granules of Stimulated Peripheral Blood Neutrophils.
  123. (2000). Properdin, the Positive Regulator of Complement, is Highly C-Mannosylated.
  124. (1988). Properdin, the Terminal Complement Components, Thrombospondin and the Circumsporozoite Protein of Malaria Parasites Contain Similar Sequence Motifs.
  125. (1993). Properdin: Approaching Four Decades of Research.
  126. (1975). Properdin: Binding to C3b and Stabilization of the C3b-Dependent C3
  127. (1968). Properties of Highly Purified Human Properdin.
  128. (2001). Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles.
  129. (2003). Proteomic and Biochemical Analyses of Human B Cell-Derived Exosomes. Potential Implications for their Function and Multivesicular Body Formation.
  130. (1995). Recurrent Meningococcal Septicaemia and Properdin Deficiency.
  131. (1996). Regulation of Alternative Pathway Activation and C3a Production by Adipose Cells.
  132. (2007). Role of Mast Cells in Allergic and Non-Allergic Immune Responses:
  133. (2000). Specificity Controls for Immunocytochemical Methods.
  134. (1997). Stem Cell Factor and Hematopoiesis.
  135. (1978). Synthesis of Factors D, B and P of the Alternative Pathway of Complement Activation, as well as of C3, by GuineaPig Peritoneal Macrophages in Vitro.
  136. (2004). The Alternative Activation Pathway and Complement Component C3 are Critical for a Protective Immune Response Against Pseudomonas Aeruginosa in a Murine Model of Pneumonia.
  137. (2006). The Central Role of the Alternative Complement Pathway in Human Disease.
  138. (2002). The Classical Pathway is the Dominant Complement Pathway Required for Innate Immunity to Streptococcus Pneumoniae Infection in Mice.
  139. (2008). The Complement Protein Properdin Binds Apoptotic T Cells and Promotes Complement Activation and Phagocytosis.
  140. (2004). The Complement System in Regulation of Adaptive Immunity.
  141. (2004). The Dimeric and Trimeric Solution Structures of the Multidomain Complement Protein Properdin by X-Ray Scattering, Analytical Ultracentrifugation and Constrained Modelling.
  142. (2007). The Effects of Glycosaminoglycans on Coagulation: A Thromboelastographic Study. Blood Coagul.
  143. (2003). The Endothelium as Physiological Source of Properdin:
  144. (2002). The iCycler iQTM Detection System for Evaluating Reference Gene Expression in Normal Human Tissue.
  145. (2005). The Immunogenicity of Dendritic CellDerived Exosomes. Blood Cells Mol.
  146. (2004). The Impact of the Inflammatory Response on Coagulation.
  147. (2008). The Initiating Proteases of the Complement System: Controlling the Cleavage.
  148. (2004). The Innate Immune Response to Pneumococcal Lung Infection: The Untold Story. Trends Immunol.
  149. (2004). The Pro-Apoptotic Protein Bim is a Convergence Point for cAMP/protein Kinase A- and Glucocorticoid-Promoted Apoptosis of Lymphoid Cells.
  150. (2002). The Role of Mast Cells in Host Defense and their Subversion by Bacterial Pathogens.
  151. (2006). The Role of Properdin in the Assembly of the Alternative Pathway C3
  152. (1990). The Spleen is Not a Major Synthetic Site of Alternative Pathway Components.
  153. (1963). The use of Lead Citrate at High pH as an Electron-Opaque Stain in Electron Microscopy.
  154. (2004). The Virulence Function of Streptococcus Pneumoniae Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection.
  155. (2005). Thromboelastography Measurements of Whole Blood from Factor VIII-Deficient Mice Supplemented with rFVIII.
  156. (2000). Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2. Regulation of Metalloproteinase Activity.
  157. (1998). to Distinct Mutations.
  158. (2007). to Mediate Efficient Decay.
  159. (2005). Toll-Like Receptor 2 Deficiency Delays Pneumococcal Phagocytosis and Impairs Oxidative Killing by Granulocytes.
  160. (2007). Transcription Factors in Myeloid Development: Balancing Differentiation with Transformation.
  161. (2001). Transforming Growth Factor-Beta-Mediated Mast Cell Migration Depends on Mitogen-Activated Protein Kinase Activity.
  162. (1999). Two genes from the capsule of Aeromonas hydrophila (serogroup O:34) confer serum resistance to Escherichia coli K12 strains.
  163. (2007). Use of Serum Or Buffer-Changed EDTA-Plasma in a Rapid, Inexpensive, and Easy-to-Perform Hemolytic Complement Assay for Differential Diagnosis of Systemic Lupus Erythematosus and Monitoring of Patients with the Disease.
  164. (2005). using its Natural Ligand C3dg: Activation without Engagement of an Inhibitory Signaling Pathway.
  165. (1998). Vaccination Against Meningococcus in Complement-Deficient Individuals.
  166. (2003). Virus Complement Evasion Strategies.
  167. (1975). White Pulp Compartments in the Spleen of Rats and Mice. A Light and Electron Microscopic Study of Lymphoid and Non-Lymphoid Cell Types in T- and B-Areas. Cell Tissue Res.
  168. (1998). World Health Organisation Meeting on Maternal and Neonatal Pneumococcal Immunization.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.